NCT00125736已完成4 期
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 520
- 主要终点
- Ratio of S2-stage transition at 8 weeks after the study administration.
研究概览
简要总结
The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.
详细描述
The efficacy and safety of E0671 in combination with Rabeprazole Sodium (i.e., 10 mg/day of rabeprazole sodium and 150 mg/day of E0671) will be investigated in patients with gastric ulcer in a multicenter, randomized, double-blind, parallel-group comparative study using a placebo control group (10 mg/day of rabeprazole sodium and placebo for E0671).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
E0671 combination group
Experimental
干预措施: E0671 (Drug)
E0671 combination group
Experimental
干预措施: rabeprazole sodium (Drug)
placebo combination group
Placebo Comparator
干预措施: rabeprazole sodium (Drug)
placebo combination group
Placebo Comparator
干预措施: E0671 placebo (Drug)
结局指标
主要结局
Ratio of S2-stage transition at 8 weeks after the study administration.
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerBRAF V600E-mutant Metastatic Colorectal CancerNCT03693170Pierre Fabre Medicament95
已完成
3 期
A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPDCOPDNCT00308191Dey128
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
已完成
3 期
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 MonotherapyEssential HypertensionNCT06121518Chong Kun Dang Pharmaceutical235
已完成
3 期
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)Benign Prostatic HyperplasiaNCT00127179Organon and Co600